M.D. Anderson Cancer Center: Colonic Neoplasms trials

The registry lists 21 Colonic Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 1 are open to participants now and 2 have results posted.

Phase 1 7Phase 2 7No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Chronic Loose Stools Following Right-sided Hemicolectomy for Colon Cancer and the Association With Bile Acid Malabsorption and Small Intestinal Bacterial Overgrowth Using a Novel Sampling DeviceRecruitingNCT06927011
• M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite InstabilityCompletedNCT03436563Phase 1/2Results posted
• Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerCompletedNCT03428126Phase 2Results posted
• The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon CancerActive, not recruitingNCT05961709Phase 2
• Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal CancerActive, not recruitingNCT05722327Phase 1
• Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) InterventionActive, not recruitingNCT05677048Not applicable
• A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)CompletedNCT05040568Phase 1
• Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse EventsActive, not recruitingNCT05038254Not applicable
• DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual DiseaseCompletedNCT05036109Not applicable
• LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04616183Phase 1/2
• SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 TrialActive, not recruitingNCT04599140Phase 1/2
• Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04017650Phase 1/2
• 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in PatientsActive, not recruitingNCT03168737Phase 1
• Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing TechniquesActive, not recruitingNCT03151564Not applicable
• Young-Onset Colorectal CancerActive, not recruitingNCT02863107
• The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)Status unknownNCT01447199
• Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By SurgeryStatus unknownNCT00985400Not applicable
• Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to LiverWithdrawnNCT00766220Phase 2
• Combined Colon and Endometrial Cancer Screening in Women With HNPCCCompletedNCT00510796
• Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) PatientsCompletedNCT00508846
• Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer PatientsStatus unknownNCT00354705